Literature DB >> 16691468

SERCA2a in heart failure: role and therapeutic prospects.

Davide Gianni1, Joachim Chan, Judith K Gwathmey, Federica del Monte, Roger J Hajjar.   

Abstract

Ca(2+) is a key molecule controlling several cellular processes, from fertilization to cell death, in all cell types. In excitable and contracting cells, such as cardiac myocytes, Ca(2+) controls muscle contractility. The spatial and temporal segregation of Ca(2+) concentrations are central to maintain its concentration gradients across the cells and the cellular compartments for proper function. SERCA2a is a cornerstone molecule for maintaining a balanced concentration of Ca(2+) during the cardiac cycle, since it controls the transport of Ca(2+) to the sarcoplasmic reticulum (SR) during relaxation. Alterations of the activity of this pump have been widely investigated, emphasizing its central role in the control of Ca(2+) homeostasis and consequently in the pathogenesis of the contractile defect seen with heart failure. This review focuses on the molecular characteristics of the pump, its role during the cardiac cycle and the prospects derived from the manipulation of SERCA2a for heart failure treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16691468     DOI: 10.1007/s10863-005-9474-z

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   3.853


  68 in total

1.  Altered dose response to beta-agonists in SERCA1a-expressing hearts ex vivo and in vivo.

Authors:  Sabine Huke; Vikram Prasad; Michelle L Nieman; Kalpana J Nattamai; Ingrid L Grupp; John N Lorenz; Muthu Periasamy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-09       Impact factor: 4.733

2.  Functional consequences of alterations to hydrophobic amino acids located at the M4S4 boundary of the Ca(2+)-ATPase of sarcoplasmic reticulum.

Authors:  B Vilsen; J P Andersen; D H MacLennan
Journal:  J Biol Chem       Date:  1991-10-05       Impact factor: 5.157

3.  Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure.

Authors:  U Schmidt; R J Hajjar; P A Helm; C S Kim; A A Doye; J K Gwathmey
Journal:  J Mol Cell Cardiol       Date:  1998-10       Impact factor: 5.000

4.  Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes.

Authors:  J M O'Donnell; C M Sumbilla; H Ma; I K Farrance; M Cavagna; M G Klein; G Inesi
Journal:  Circ Res       Date:  2001-03-02       Impact factor: 17.367

5.  Sarcolipin regulates the activity of SERCA1, the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2+-ATPase.

Authors:  A Odermatt; S Becker; V K Khanna; K Kurzydlowski; E Leisner; D Pette; D H MacLennan
Journal:  J Biol Chem       Date:  1998-05-15       Impact factor: 5.157

6.  Functional and structural roles of critical amino acids within the"N", "P", and "A" domains of the Ca2+ ATPase (SERCA) headpiece.

Authors:  Hailun Ma; David Lewis; Cheng Xu; Giuseppe Inesi; Chikashi Toyoshima
Journal:  Biochemistry       Date:  2005-06-07       Impact factor: 3.162

7.  Relation between steady-state force and intracellular [Ca2+] in intact human myocardium. Index of myofibrillar responsiveness to Ca2+.

Authors:  J K Gwathmey; R J Hajjar
Journal:  Circulation       Date:  1990-10       Impact factor: 29.690

Review 8.  Regulation of sarco(endo)plasmic reticulum Ca2+ adenosine triphosphatase by phospholamban and sarcolipin: implication for cardiac hypertrophy and failure.

Authors:  Michio Asahi; Hiroyuki Nakayama; Michihiko Tada; Kinya Otsu
Journal:  Trends Cardiovasc Med       Date:  2003-05       Impact factor: 6.677

9.  Functional consequences of alterations to amino acids located in the catalytic center (isoleucine 348 to threonine 357) and nucleotide-binding domain of the Ca2+-ATPase of sarcoplasmic reticulum.

Authors:  K Maruyama; D M Clarke; J Fujii; G Inesi; T W Loo; D H MacLennan
Journal:  J Biol Chem       Date:  1989-08-05       Impact factor: 5.157

10.  Altered diastolic [Ca2+]i handling in human ventricular myocytes from patients with terminal heart failure.

Authors:  D J Beuckelmann; M Näbauer; C Krüger; E Erdmann
Journal:  Am Heart J       Date:  1995-04       Impact factor: 4.749

View more
  24 in total

Review 1.  SERCA2a: a key protein in the Ca2+ cycle of the heart failure.

Authors:  Liu Zhihao; Ni Jingyu; Li Lan; Sarhene Michael; Guo Rui; Bian Xiyun; Liu Xiaozhi; Fan Guanwei
Journal:  Heart Fail Rev       Date:  2020-05       Impact factor: 4.214

2.  Sleeve gastrectomy in obese Wistar rats improves diastolic function and promotes cardiac recovery independent of weight loss.

Authors:  Hailey Hayes; Jacob Patz; John Corbett; Muhammad Z Afzal; Jennifer Strande; Tammy L Kindel
Journal:  Surg Obes Relat Dis       Date:  2019-03-23       Impact factor: 4.734

3.  Effects of cardiac-restricted overexpression of the A(2A) adenosine receptor on adriamycin-induced cardiotoxicity.

Authors:  Eman A Hamad; Xue Li; Jianliang Song; Xue-Qian Zhang; Valerie Myers; Hajime Funakoshi; Jin Zhang; Jufang Wang; Jifen Li; David Swope; Ashley Madonick; John Farber; Glenn L Radice; Joseph Y Cheung; Tung O Chan; Arthur M Feldman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-02       Impact factor: 4.733

4.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.

Authors:  Mariell Jessup; Barry Greenberg; Donna Mancini; Thomas Cappola; Daniel F Pauly; Brian Jaski; Alex Yaroshinsky; Krisztina M Zsebo; Howard Dittrich; Roger J Hajjar
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

5.  The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase.

Authors:  Kobra Haghighi; Tracy Pritchard; Julie Bossuyt; Jason R Waggoner; Qunying Yuan; Guo-Chang Fan; Hanna Osinska; Ahmad Anjak; Jack Rubinstein; Jeffrey Robbins; Donald M Bers; Evangelia G Kranias
Journal:  J Mol Cell Cardiol       Date:  2011-12-01       Impact factor: 5.000

6.  Immunosuppression decreases inflammation and increases AAV6-hSERCA2a-mediated SERCA2a expression.

Authors:  Xiaodong Zhu; Charles F McTiernan; Navin Rajagopalan; Hemal Shah; David Fischer; Yoshiya Toyoda; Dustin Letts; Jonathan Bortinger; Gregory Gibson; Wenyu Xiang; Kenneth McCurry; Michael Mathier; Joseph C Glorioso; Barry London
Journal:  Hum Gene Ther       Date:  2012-07-11       Impact factor: 5.695

7.  Reduced SERCA2a converts sub-lethal myocardial injury to infarction and affects postischemic functional recovery.

Authors:  M A Hassan Talukder; Fuchun Yang; Yoshinori Nishijima; Chun-An Chen; Anuradha Kalyanasundaram; Muthu Periasamy; Jay L Zweier
Journal:  J Mol Cell Cardiol       Date:  2008-11-12       Impact factor: 5.000

8.  Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017.

Authors:  T Na; D Z Dai; X Y Tang; Y Dai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-08       Impact factor: 3.000

9.  Sexually dimorphic myofilament function and cardiac troponin I phosphospecies distribution in hypertrophic cardiomyopathy mice.

Authors:  Laurel A K McKee; Hao Chen; Jessica A Regan; Samantha M Behunin; Jeffery W Walker; John S Walker; John P Konhilas
Journal:  Arch Biochem Biophys       Date:  2013-01-23       Impact factor: 4.013

10.  Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

Authors:  Brian E Jaski; Mariell L Jessup; Donna M Mancini; Thomas P Cappola; Daniel F Pauly; Barry Greenberg; Kenneth Borow; Howard Dittrich; Krisztina M Zsebo; Roger J Hajjar
Journal:  J Card Fail       Date:  2009-04       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.